Advertisement

International Microbiology

, Volume 22, Issue 1, pp 69–80 | Cite as

Integration of virtual screening and susceptibility test to discover active-site subpocket-specific biogenic inhibitors of Helicobacter pylori shikimate dehydrogenase

  • Kuifeng Wang
  • Min Zhu
  • Yongzhi Tang
  • Junyan Liu
  • Fei Yan
  • Zhenjun Yu
  • Jiansheng ZhuEmail author
Original Article
  • 38 Downloads

Abstract

Shikimate dehydrogenase (HpSDH) (EC 1.1.1.25) is a key enzyme in the shikimate pathway of Helicobacter pylori (H. pylori), which catalyzes the NADPH-dependent reversible reduction of 3-dehydroshikimate to shikimate. Targeting HpSDH has been recognized as an attractive therapeutic strategy against H. pylori infection. Here, the catalytic active site in the crystal structure of HpSDH in complex with its substrate NADPH and product shikimate was examined in detail; the site can be divided into three spatially separated subpockets that separately correspond to the binding regions of shikimate, NADPH dihydronicotinamide moiety, and NADPH adenine moiety. Subsequently, a cascading protocol that integrated virtual screening and antibacterial test was performed against a biogenic compound library to identify biologically active, subpocket-specific inhibitors. Consequently, five, eight, and six promising compounds for, respectively, subpockets 1, 2, and 3 were selected from the top-100 docking-ranked hits, from which 11 compounds were determined to have high or moderate antibacterial potencies against two reference H. pylori strains, with MIC range between 8 and 93 μg/mL. It is found that the HpSDH active site prefers to accommodate amphipathic and polar inhibitors that consist of an aromatic core as well as a number of oxygen-rich polar/charged substituents such as hydroxyl, carbonyl, and carboxyl groups. Subpockets 1- and 2-specific inhibitors exhibit a generally higher activity than subpocket 3-specific inhibitors. Molecular dynamics simulations revealed an intense nonbonded network of hydrogen bonds, π-π stacking, and van der Waals contacts at the tightly packed complex interfaces of active-site subpockets with their cognate inhibitors, conferring strong stability and specificity to these complex systems. Binding energetic analysis demonstrated that the identified potent inhibitors can target their cognate subpockets with an effective selectivity over noncognate ones.

Keywords

Helicobacter pylori Shikimate dehydrogenase Biogenic compound Subpocket Virtual screening Rational drug discovery 

Notes

Funding information

This work was supported by the Zhejiang Provincial Medical Science and Technology Project (No. 2016KYA187).

References

  1. Abadi ATB (2014) Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int 2014:124607Google Scholar
  2. Ames BN, Gurney EG, Miller JA, Bartsch H (1972) Carcinogens as frameshift mutagens: metabolites and derivatives of 2-acetylaminofluorene and other aromatic amine carcinogens. Proc Natl Acad Sci U S A 69:3128–3132CrossRefGoogle Scholar
  3. An B, Moon BS, Kim H, Lim HC, Lee YC, Lee G, Kim SH, Park M, Kim JB (2013) Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea. Ann Lab Med 33:415–419CrossRefGoogle Scholar
  4. Avitia-Domínguez C, Sierra-Campos E, Salas-Pacheco JM, Nájera H, Rojo-Domínguez A, Cisneros-Martínez J, Téllez-Valencia A (2014) Inhibition and biochemical characterization of methicillin-resistant Staphylococcus aureus shikimate dehydrogenase: an in silico and kinetic study. Molecules 19:4491–4509CrossRefGoogle Scholar
  5. Bai Z, Hou S, Zhang S, Li Z, Zhou P (2017) Targeting self-binding peptides as a novel strategy to regulate protein activity and function: a case study on the proto-oncogene tyrosine protein kinase c-Src. J Chem Inf Model 57:835–845CrossRefGoogle Scholar
  6. Bayly CI, Cieplak P, Cornell WD, Kollman PA (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges –– the RESP model. J Phys Chem 97:10269–10280CrossRefGoogle Scholar
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235–242CrossRefGoogle Scholar
  8. Blaser MJ (2006) Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep 7:956–960CrossRefGoogle Scholar
  9. Darden T, York D, Pedersen L (1993) Particale mesh Ewald: and N.log(N) method for Ewald sums in large systems. J Chem Phys 98:10089–10092CrossRefGoogle Scholar
  10. De Francesco V, Ierardi E, Hassan C, Zullo A (2012) Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther 3:68–73CrossRefGoogle Scholar
  11. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, Mukhopadhyay AK (2009) Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother 53:1592–1597CrossRefGoogle Scholar
  12. Debraekeleer A, Remaut H (2018) Future perspective for potential Helicobacter pylori eradication therapies. Future Microbiol [Epub ahead of print,  https://doi.org/10.2217/fmb-2017-0115]
  13. Duan Y, Wu C, Chowdhury SS, Lee MC, Xiong GM, Zhang W, Yang R, Cieplak P, Luo R, Lee TS, Caldwell J, Wang JM, Kollman P (2003) A point-charge force field for molecular mechanics simulations of proteins. J Comput Chem 24:1999–2012CrossRefGoogle Scholar
  14. Dunn BE, Cohen H, Blaser MJ (1997) Helicobacter pylori. Clin Microbiol Rev 10:720–741CrossRefGoogle Scholar
  15. Gong H, Yuan Z, Zhan L (2016) High-throughput screening against ~6.1 million structurally diverse, lead-like compounds to discover novel ROCK inhibitors for cerebral injury recovery. Mol Divers 20:537–549CrossRefGoogle Scholar
  16. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A (2005) H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res 33:W368–W371CrossRefGoogle Scholar
  17. Han C, Wang L, Yu K, Chen L, Hu L, Chen K, Jiang H, Shen X (2006) Biochemical characterization and inhibitor discovery of shikimate dehydrogenase from Helicobacter pylori. FEBS J 273:4682–4692CrossRefGoogle Scholar
  18. Homeyer N, Gohlke H (2012) Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method. Mol Inf 31:114–122CrossRefGoogle Scholar
  19. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR (1999) MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28–33CrossRefGoogle Scholar
  20. Irwin JJ, Shoichet BK (2005) ZINC –– a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177–182CrossRefGoogle Scholar
  21. Isa MA, Majumdhar RS, Haider S (2018) In silico docking and molecular dynamics simulation of 3-dehydroquinate synthase (DHQS) from Mycobacterium tuberculosis. J Mol Model 24:132CrossRefGoogle Scholar
  22. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79(2):926-935CrossRefGoogle Scholar
  23. Karczewska E, Klesiewicz K, Wojtas-Bonior I, Skiba I, Sito E, Czajecki K, Zwolińska-Wcisło M, Budak A (2014) Levofloxacin resistance of Helicobacter pylori strains isolated from patients in southern Poland, between 2006-2012. Acta Pol Pharm 71:477–483Google Scholar
  24. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS (2004) Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 48:4843–4847CrossRefGoogle Scholar
  25. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889–897CrossRefGoogle Scholar
  26. Kusters JG, van Vliet AH, Kuipers EJ (2006) Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 19:449–490CrossRefGoogle Scholar
  27. Lee SK, Chang GS, Lee IH, Chung JE, Sung KY, No KT (2004) The PreADME: PC-based program for batch predication of ADME properties. EuroQSAR 2004:9.5–9.910Google Scholar
  28. Lee HK, Song HE, Lee HB, Kim CS, Koketsu M, Ngan LT, Ahn YJ (2014) Growth inhibitory, bactericidal, and morphostructural effects of dehydrocostus lactone from Magnolia sieboldii leaves on antibiotic-susceptible and -resistant strains of Helicobacter pylori. PLoS One 9:e95530CrossRefGoogle Scholar
  29. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM (2003) The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 3:1125–1154CrossRefGoogle Scholar
  30. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26CrossRefGoogle Scholar
  31. Lorber DM, Shoichet BK (1998) Flexible ligand docking using conformational ensembles. Protein Sci 7:938–950CrossRefGoogle Scholar
  32. Luo H, Du T, Zhou P, Yang L, Mei H, Ng H, Zhang W, Shu M, Tong W, Shi L, Mendrick DL, Hong H (2015) Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. Comb Chem High Throughput Screen 18:296–304CrossRefGoogle Scholar
  33. Mysinger MM, Shoichet BK (2010) Rapid context-dependent ligand desolvation in molecular docking. J Chem Inf Model 50:1561–1573CrossRefGoogle Scholar
  34. Ngan CH, Bohnuud T, Mottarella SE, Beglov D, Villar EA, Hall DR, Kozakov D, Vajda S (2012) FTMAP: extended protein mapping with user-selected probe molecules. Nucleic Acids Res 40:W271–W275CrossRefGoogle Scholar
  35. Peek J, Shi T, Christendat D (2014) Identification of novel polyphenolic inhibitors of shikimate dehydrogenase (AroE). J Biomol Screen 19:1090–1098CrossRefGoogle Scholar
  36. Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, Coggins JR, Coombs GH, Milhous WK, Tzipori S, Ferguson DJ, Chakrabarti D, McLeod R (1998) Evidence for the shikimate pathway in apicomplexan parasites. Nature 393:801–805CrossRefGoogle Scholar
  37. Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23:327–341CrossRefGoogle Scholar
  38. Sahu M, Nerkar AG, Chikhale HU, Sawant SD (2015) In silico screening, synthesis and pharmacological screening of quinazolinones containing oxazepinone ring as NMDA receptor antagonists for anticonvulsant activity: part-I. J Young Pharm 7:21–27Google Scholar
  39. Sisto F, Scaltrito MM, Russello G, Bonomi A, Dubini F (2009) Antimicrobial susceptibility testing of Helicobacter pylori determined by microdilution method using a new medium. Curr Microbiol 58:559–563CrossRefGoogle Scholar
  40. Tian F, Lv Y, Zhou P, Yang L (2011) Characterization of PDZ domain-peptide interactions using an integrated protocol of QM/MM, PB/SA, and CFEA analyses. J Comput Aided Mol Des 25:947–958CrossRefGoogle Scholar
  41. Tian F, Yang C, Wang C, Guo T, Zhou P (2014) Mutatomics analysis of the systematic thermostability profile of Bacillus subtilis lipase A. J Mol Model 20:2257CrossRefGoogle Scholar
  42. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157–1174CrossRefGoogle Scholar
  43. Wang K, Yang C, Lin G, Wang G, Zhu J (2017) Structure-based rational design of peptide inhibitors to disrupt the recognition and interaction between hepatitis B virus large envelope protein and human hepatocyte receptor γ2-adaptin. Med Chem Res 26:2824–2831CrossRefGoogle Scholar
  44. Word JM, Lovell SC, Richardson JS, Richardson DC (1999) Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol 285:1735–1747CrossRefGoogle Scholar
  45. Yang C, Wang C, Zhang S, Huang J, Zhou P (2015a) Structural and energetic insights into the intermolecular interaction among human leukocyte antigens, clinical hypersensitive drugs and antigenic peptides. Mol Simul 41:741–751CrossRefGoogle Scholar
  46. Yang C, Zhang S, He P, Wang C, Huang J, Zhou P (2015b) Self-binding peptides: folding or binding. J Chem Inf Model 55:329–342CrossRefGoogle Scholar
  47. Yang C, Zhang S, Bai Z, Hou S, Wu D, Huang J, Zhou P (2016) A two-step binding mechanism for the self-binding peptide recognition of target domains. Mol BioSyst 12:1201–1213CrossRefGoogle Scholar
  48. Yu H, Zhou P, Deng M, Shang Z (2014) Indirect readout in protein-peptide recognition: a different story from classical biomolecular recognition. J Chem Inf Model 54:2022–2032CrossRefGoogle Scholar
  49. Zhou P, Wang C, Tian F, Ren Y, Yang C, Huang J (2013a) Biomacromolecular quantitative structure-activity relationship (BioQSAR): a proof-of-concept study on the modeling, prediction and interpretation of protein-protein binding affinity. J Comput Aided Mol Des 27:67–78CrossRefGoogle Scholar
  50. Zhou P, Yang C, Ren Y, Wang C, Tian F (2013b) What are the ideal properties for functional food peptides with antihypertensive effect? A computational peptidology approach. Food Chem 141:2967–2973CrossRefGoogle Scholar
  51. Zhou P, Zhang S, Wang Y, Yang C, Huang J (2016) Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. J Biomol Struct Dyn 34:1806–1817CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Kuifeng Wang
    • 1
  • Min Zhu
    • 1
  • Yongzhi Tang
    • 1
  • Junyan Liu
    • 1
  • Fei Yan
    • 1
  • Zhenjun Yu
    • 1
  • Jiansheng Zhu
    • 1
    Email author
  1. 1.Department of Infectious DiseasesAffiliated Taizhou Hospital of Wenzhou Medical UniversityTaizhouChina

Personalised recommendations